Moreover, SMN expression levels were found to be consistently higher in CNS tissues, indicating a higher requirement for SMN in neural tissues compared with non-neuronal tissues, comparable with the disease phenotypes observed in SMA patients and mouse models. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.